Top news from MedWatch this week
Monday
Lundbeck parks Alzheimer’s drug hope as there is no evidence it works
GN and Demant lost ground with veterans in February
Bavarian Nordic enters license agreement with Nuance Pharma on RSV candidate
Bavarian Nordic could be first on the RSV market in China
Tuesday
Novo Nordisk recruits 500 people for Alzheimer’s trial
Orphazyme files for delisting in US
Orphazyme withdraws marketing application ahead of final vote
Heavy-handed Covid-19 approach in China causes problems for hearing aid firms
The Lundbeck Foundation delivers record-breaking result
Wednesday
Lundbeck faces criticism over new share structure
Lundbeck chair on shareholder criticism: Share split benefits everyone
Lundbeck has halted studies in Russia, continues to supply medicine
GN Hearing wants an EBITA margin of over 20 percent in 2024
Thursday
Leo Pharma has applied for expanded approval for eczema treatment in EU
Ascendis Pharma to raise capital with convertible notes
Novo CEO condemns invasion of Ukraine – but keeps Russian factory running
Friday
CHMP approves 5 new drugs in March
WS Audiology and GN settle false advertising case in US
Novo Nordisk chair believes in globalization despite international tensions
.jpg&w=384&q=75)
